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ABSTRACT 
Hepatitis B is one of the most prevalent viral diseases worldwide and is a major public 
health concern, particularly in Asia. Of the 350 million people suffering from chronic 
hepatitis B virus (HBV) infection worldwide, approximately 75% are found in Asia. 
HBV is a noncytopathic, hepatotropic virus that causes acute and chronic hepatitis and 
hepatocellular carcinoma (HCC). Virus-specific T cells have been found to be 
associated with the control of HBV infection, but have also been implicated as the 
principal effectors of liver damage. Although the mechanisms responsible for liver 
inflammation have been nicely demonstrated in animal models, we still lack evidence 
for these events in humans. We therefore studied the role of HBV-specific CD8 T 
cells in different phases of HBV infection. Analysis of the kinetics of innate and 
adaptive immune activation during hepatic flares in chronic hepatitis B revealed that 
the rebound of HBV replication following therapy withdrawal occurred without 
triggering any innate immune activation, with the exception of increased serum 
CXCL-8. Hepatic flares were temporally associated with high serum levels of the 
IFN-γ inducible chemokines CXCL-9 and CXCL-10. Both were differentially 
produced in liver injury present in acute or chronic patients and displayed different in 
vitro requirements for activation. The inflammatory potential of virus-specific T cells 
was characterized by analysing their ability to produce IL-17 and CXCL-8 during 
different phases of HBV infection. We also determined whether cytokines present in the 
liver during inflammation (IL-7 and IL-15) could license virus-specific T cells with 
additional cytokine profiles that contribute to tissue inflammation. Our results showed 
that HBV-specific T cells produced CXCL-8, but not IL-17, during periods of liver 
inflammation in acute or chronic patients. HBV-specific T cells producing CXCL-8 
could be expanded from acute/resolved patients in the presence of IL-7 and IL-15, 
suggesting that virus-specific T cells can acquire through exposure to environmental 
factors, a cytokine/chemokine profile capable of contributing to parenchymal 
inflammation. 
Despite that today’s antiviral drugs efficiently decrease HBV viral load to 
undetectable levels, they fail to eradicate infection due to the persistence of HBV 
covalently closed circular DNA in hepatocytes. Long-term treatment is also 
expensive, and may result in problems of toxicity and emergence of resistant viruses. 
Attempts to restore HBV-specific immunity in chronic patients with therapeutic 
vaccines have had little success. We therefore developed a new strategy based on T 
cell receptor (TCR) gene transfer to reconstitute the defective antiviral immunity of 
chronic patients. DNA encoding the HBV-specific TCR alpha/beta chain was cloned 
from immunodominant HBV-specific CD8 T cells from acute/resolved patients. The 
TCR genes were transferred to primary human T cells using retroviral transduction or 
mRNA electroporation. Transgenic TCRs were efficiently expressed on T cells of 
chronic HBV/HCC patients and reconstituted fully functional HBV-specific T cells. 
Furthermore, these TCR-redirected T cells recognized and lysed natural HCC lines with 
HBV DNA integration. Despite a transient functionality, the TCR mRNA 
electroporated T cells efficiently prevented tumor seeding and suppressed the growth of 
established tumors in a xenograft model of HCC. Overall, we developed a method that 
represents a practical approach to cell therapy of HCC and its inherently self-limiting 
toxicity suggests potential for application in other HBV-related pathologies. 
